title: Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
abstract: A two-tier system in which ovarian epithelial carcinomas are subdivided into type I and type II tumors has been proposed on the basis of recent molecular pathogenesis findings. Type I tumors, unrelated to tumor protein p53 (TP53) mutations, show favorable prognosis in a slow step-wise process, whereas type II tumors, related to TP53 mutations, contribute to poor prognosis. Ovarian serous carcinomas with excessive psammoma bodies behave like type I tumors. However, their etiology and prognostic significance remain obscure. The objective of the present study was to evaluate the characteristic features and potential relevance of psammoma bodies to the clinical outcome of 44 patients with serous carcinomas with long-term follow-up. The 5- and 10-year survival rates were significantly different between the serous carcinomas with less than 5% area of psammoma bodies and those at least 5% area (P < 0.01). All tumors with at least 5% area were both diploid and immunohistochemically negative for TP53 mutations. All patients with these tumors, including eight with International Federation of Gynecology and Obstetrics (FIGO) stages III or IV disease, survived more than 5 years and their 10-year survival rate was 76%. In multivariate analysis using clinical parameters, the apparent existence of psammoma bodies was an indication to view serous carcinomas as type I tumors with long-term survival. Our results suggested that the formation of psammoma bodies is associated with increased apoptotic tumor cell death related to normal TP53 function. The pathological findings of psammoma bodies might contribute to the consideration of pathogenesis and to the development of prognostic prediction rules for serous carcinomas.
authors.affiliation: Department of Gynecology and Reproductive Medicine and Surgery, Kumamoto University, Kumamoto City, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Motohara
authors.forename: Hironori
authors.initials: H
authors.lastname: Tashiro
authors.forename: Yo
authors.initials: Y
authors.lastname: Miyahara
authors.forename: Isao
authors.initials: I
authors.lastname: Sakaguchi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ohtake
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Katabuchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018284:Cystadenocarcinoma, Serous / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate
references.citation: Am J Pathol. 2004 May;164(5):1511-8
references.pmid: 15111296
references.citation: Blood. 1993 Mar 15;81(6):1607-13
references.pmid: 7680921
references.citation: Jpn J Cancer Res. 1992 Sep;83(9):978-84
references.pmid: 1429209
references.citation: Gynecol Oncol. 1983 Jun;15(3):370-80
references.pmid: 6862292
references.citation: Gynecol Oncol. 2001 Apr;81(1):10-7
references.pmid: 11277643
references.citation: Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:135-66
references.pmid: 14763172
references.citation: Cancer. 1988 Nov 15;62(10):2212-22
references.pmid: 3179935
references.citation: Scanning Microsc. 1995;9(4):1137-75; discussion 1175-8
references.pmid: 8819895
references.citation: Pathol Int. 2000 Jul;50(7):531-5
references.pmid: 10886734
references.citation: Cancer. 1977 Jun;39(6):2451-9
references.pmid: 872045
references.citation: Adv Cancer Res. 2001;82:55-84
references.pmid: 11447765
references.citation: Eur J Gynaecol Oncol. 1988;9(3):234-41
references.pmid: 3391195
references.citation: Br J Cancer. 1972 Aug;26(4):239-57
references.pmid: 4561027
references.citation: Exp Cell Res. 1996 Aug 1;226(2):387-97
references.pmid: 8806443
references.citation: J Clin Oncol. 1988 Feb;6(2):282-90
references.pmid: 3276825
references.citation: Int J Gynaecol Obstet. 2005 Mar;88(3):286-91
references.pmid: 15733883
references.citation: Br J Cancer. 2005 Jul 11;93(1):116-23
references.pmid: 15956975
references.citation: Int J Clin Oncol. 2001 Aug;6(4):177-82
references.pmid: 11706555
references.citation: Gynecol Oncol. 1982 Aug;14(1):6-14
references.pmid: 7095589
references.citation: Int J Gynecol Pathol. 1990;9(2):110-21
references.pmid: 2332269
references.citation: Cancer Sci. 2003 Nov;94(11):953-9
references.pmid: 14611671
references.citation: Int Rev Cytol. 1980;68:251-306
references.pmid: 7014501
references.citation: Am J Surg Pathol. 2004 Apr;28(4):496-504
references.pmid: 15087669
references.citation: J Pathol. 2004 Mar;202(3):336-40
references.pmid: 14991899
references.citation: Int J Gynecol Pathol. 1998 Jan;17(1):54-60
references.pmid: 9475193
references.citation: Am J Surg Pathol. 1998 Jul;22(7):849-62
references.pmid: 9669347
references.citation: Gynecol Oncol. 1992 Nov;47(2):159-66
references.pmid: 1468693
references.citation: Obstet Gynecol. 1982 May;59(5):576-82
references.pmid: 7070728
references.citation: Am J Obstet Gynecol. 1971 Jan 1;109(1):113-8
references.pmid: 4321483
references.citation: Eur J Cancer Clin Oncol. 1989 Apr;25(4):711-20
references.pmid: 2714347
references.citation: Am J Pathol. 1997 Jan;150(1):177-85
references.pmid: 9006334
references.citation: Cancer. 1972 May;29(5):1326-35
references.pmid: 5021621
references.citation: Cancer. 1992 Jun 1;69(11):2668-75
references.pmid: 1571896
references.citation: Acta Pathol Microbiol Scand. 1965;:Suppl 176:1-90
references.pmid: 5837391
references.citation: Arch Gynecol Obstet. 1990;247(3):125-9
references.pmid: 2369150
references.citation: Int Rev Cytol. 2005;242:1-54
references.pmid: 15598466
references.citation: Carcinogenesis. 2009 Mar;30(3):423-31
references.pmid: 19126650
references.citation: Cancer Res. 1996 May 1;56(9):2178-84
references.pmid: 8616869
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: Anticancer Res. 2001 May-Jun;21(3B):1723-30
references.pmid: 11497252